Supplementary Materials

Supplementary Material for:

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects

James G. Kublin,* Sebastian A. Mikolajczak, Brandon K. Sack, Matt E. Fishbaugher, Annette Seilie, Lisa Shelton, Tracie VonGoedert, Melike Firat, Sara Magee, Emma Fritzen, Will Betz, Heather S. Kain, Dorender A. Dankwa, Ryan W. J. Steel, Ashley M. Vaughan, D. Noah Sather, Sean C. Murphy, Stefan H. I. Kappe*

*Corresponding author. Email: stefan.kappe{at}cidresearch.org (S.H.I.K.); jkublin{at}fredhutch.org (J.G.K.)

Published 4 January 2017, Sci. Transl. Med. 9, eaad9099 (2017)
DOI: 10.1126/scitranslmed.aad9099

This PDF file includes:

  • Materials and Methods
  • Fig. S1. The creation of P. yoelii lacking p52, p36, and sap1 (Py GAP3KO).
  • Fig. S2. Photograph of application site illustrating spectrum of local reactogenicity.
  • Table S1. Primers used to produce P. yoelii lacking p52, p36, and sap1 (Py GAP3KO).
  • Table S2. Rating scale for sporozoite salivary gland load.
  • Table S3. Eligibility criteria for study volunteers.
  • Table S4. Participant demographics.
  • Table S5. Solicited adverse events—post-administration reactogenicity.
  • Table S6. Solicited adverse events—malaria signs and symptoms.
  • Table S7. All adverse events by system organ class/preferred term and severity grade.
  • Table S8. Abnormal laboratory values.
  • Table S9. CSP titer values.
  • Table S10. Functional assay values.
  • Table S11. In vivo inhibition values.

[Download PDF]